Logo

Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the Treatment of COVID-19

Share this

Lilly and Junshi Collaborate to Co-Develop Antibody Therapies for the Treatment of COVID-19

Shots:

  • Lilly will get an exclusive license to perform clinical development- manufacturing and distribution of products outside of China while Junshi will maintain all rights in Greater China
  • The collaboration will accelerate the clinical development of Junshi’s Ab therapies against COVID-19 globally. Both the companies have submitted the IND application and anticipate the initiation of clinical study in Q2’20
  •  JS016 is a recombinant mAb targeting SARS-CoV-2 surface spike protein receptor binding domain and effectively blocks the binding of viruses to host cell surface receptor ACE2 and is jointly developed by Junshi and Institute of Microbiology- Chinese Academy of Science. The company is in communication with NMPA to initiate the IND submission in China

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image:  Business Insider


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions